Ibogaine By David Dardashti Creates an Aftercare Support Network for Women
Ibogaine support for Women
MIAMI, April 27, 2024 (GLOBE NEWSWIRE) — Ibogaine By David Dardashti (IBDD) is pleased to announce the appointment of Whitney Nuckolls as the Alumni Coordinator of their free aftercare support network for women.
IBDD is always looking for innovative ways to support their clients, and this new program is a testament to that commitment. The clinic understands that there are gender specific issues that women do not always feel comfortable discussing in the presence of men. To help address this need, IBDD has decided to appoint Whitney as the coordinator for a free aftercare support network for women who have undergone ibogaine treatment at the clinic. At this time, we are not sure of the exact shape and scope of this program. We will begin by offering women who have received ibogaine treatment at our clinic the opportunity to join a WhatsApp group. We anticipate that this support network will expand as the program progresses. Whitney had this to say about her new role, “I am very excited and honored to be part of this new initiative. It is a great opportunity to create a safer and more supportive space for women who have gone through ibogaine treatment. I am always willing to support ibogaine in any way I can.”
Ibogaine By David Dardashti has appointed Whitney as the coordinator for a free aftercare support network for women who have undergone ibogaine treatment, which will include a WhatsApp group to provide a safer and more supportive space.
We encourage those who are interested in this program to reach out to IBDD to learn more. We also look forward to the potential growth of this program as we receive more feedback and create tailored solutions for our clients.
A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/db90f9fd-66be-419a-a51b-7c9bb2804f94
CONTACT: Gavriel Dardashti +17869301880 gavriel@ibogaineclinic.com
– Pharmacology modeling data presented at the European Academy of Allergy & Clinical Immunology (EAACI)…
D-bal-max D-Bal MAX Glasgow, June 15, 2025 (GLOBE NEWSWIRE) -- In the quest for enhanced…
Media ReleaseCOPENHAGEN, Denmark; June 15, 2025 Results from the EPCORE® NHL-2 trial show investigational treatment…
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response…
After a thorough clinical review, the benefit-risk for the use of Elevidys in non-ambulatory patients…
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were…
![](data:image/svg+xml;charset=utf-8,<svg height="32px" width="32px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="400px" width="1000px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
![](data:image/svg+xml;charset=utf-8,<svg height="1px" width="1px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
